Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...

Coursera Inc. (NYSE:COUR) is one of the small cap stocks with the highest upside potential. On April 23, Coursera reported its financial results for Q1 2026, highlighted by a 9% year-over-year ...

Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

This repository provides unofficial binary wheels for Pygame for Python on Windows. The files are unofficial (meaning: informal, unrecognized, personal, unsupported, no warranty, no liability, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Coursera (COUR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

If you want a more in-depth explanation/tutorial on virtual environments in Python, I'd highly suggest the videos made by Corey Schafer: Windows: Python Tutorial: VENV (Windows) - How to Use Virtual ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Have you ever wished you could generate interactive websites with HTML, CSS, and JavaScript while programming in nothing but Python? Here are three frameworks that do the trick. Python has long had a ...

More than a decade after its founding, Cour Pharmaceuticals has raised $105 million in series A funding as it advances two immune disease drugs through clinical trials. Roche, Pfizer, and Bristol ...